An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases.
VERDICT
The label
Markup
read at $81.21
BridgeBio Pharma Inc holds its Markup at $81.21.
PHPhase · the trend structure carries the Markup label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · does not pass the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-08-13
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 17 days
Price
$81.21
Valuation
N/A trailing · 219.38 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.98
OPPORTUNITY
The opportunity · what the numbers say it is worth
Read at
$81.21
N/A P/E · 219.38 fwd
Our fair value
$57.57
29% premium
Analyst target (avg)
$107.00
+32% to current
Target low $80.00Analyst target rangeTarget high $157.00
▲ current $81.21 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$81.21
you are here
Conservative
$57.57
-29%
Analyst avg
$107.00
+32%
Our fair value
$57.57
-29%
Analyst high
$157.00
+93%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish — a quality-at-a-fair-price name rather than a deep-value one.
Revenue growth
120.40%
Profit margin
-97.03%
Analyst consensus
Strong Buy · 21 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company is excluded by both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. It fails on both:
The common standard· AAOIFI Used by most halal investing apps✗ DOES NOT PASS
Our stricter standard· asset-based The one Titan applies✗ DOES NOT PASS
Why it fails. The problem is its debt ratio. Because both standards agree on this, it is a clear exclusion, not a borderline case.
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is 199.0% of its assets, above the one-third ceiling the screen allows.Fail
Interest-bearing cashCash held in interest-bearing accounts and securities is 1.9% of assets, under the one-third limit.Pass
ReceivablesMoney owed to the company is 75.8% of assets, above the 49% limit.Fail
Revenue purityOnly 4.0% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Rare disease drug meets punishing price tag
Picture families waiting years for a pill that might slow a genetic heart condition. BridgeBio has delivered Attruby and revenue is leaping 67 percent, yet the business still burns cash at a 124 percent loss margin.
We pass. The shares trade at 81 dollars against our 56 dollar fair value, a forward multiple of 138 times earnings with a narrow moat and no margin of safety. Analyst targets sit higher, but the gap between price and reality is simply too wide.
Risk sits in binary trial outcomes and the constant need for fresh capital. One missed readout or fresh competitor can erase years of progress. Analysis, not advice.
Screened names in the same industry · explore each on its own page.
TRADER
The trader read · the latest dated commentary
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 21.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 69%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (23 analysts) rates it strong buy, with a mean price target of $102. Entered 2026-07-22 · Markdown
JOURNAL
The dated journal · newest first, never edited
2026-07-22Markdown$81.38+21.8%Entry 4
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 21.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 69%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (23 analysts) rates it strong buy, with a mean price target of $102.
2026-07-18Markdown$66.80+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 69%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (23 analysts) rates it strong buy, with a mean price target of $102.
2026-07-03Markdown$66.80+0.0%Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markdown$66.80Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
RETURNS
What holding actually paid · price plus dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$64.68
+4.8%
·
$1,048
+4.8%
2 months
$74.59
-9.2%
·
$908
-9.2%
3 months
$67.98
-0.3%
·
$997
-0.3%
6 months
$74.07
-8.5%
·
$915
-8.5%
1 year
$40.09
+69.0%
·
$1,690
+69.0%
2 years
$27.83
+143.5%
·
$2,435
+143.5%
3 years
$16.00
+323.5%
·
$4,235
+323.5%
5 years
$63.93
+6.0%
·
$1,060
+6.0%
Historical returns from market close data. Past performance does not guarantee future results.
SEALED
This entry now belongs to the ledger. Whatever BBIO does next, these words stay.
BridgeBio Pharma Inc · BBIO · Markup · $81.21
Recorded 2026-08-13 · before the outcome · scored mechanically
